Firazyr
(Icatibant)ApprovedSmall molecule
TakedaFirazyr is a small molecule that works as a Bradykinin B2 Receptor Antagonist.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]
Firazyr is one of 199 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Approved.
8
Indications
19
Total Trials
2
Active Trials
198
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hereditary Angioedema5 trials
Angioedema3 trials
COVID-193 trials
6 more indications
Hereditary Angioedema (HAE)1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Aug 25, 2011
FIRAZYR
NDA NDA022150
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icatibant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]